上尿路尿路上皮癌患者微卫星不稳定/错配修复缺陷表型的协作综述
法国泌尿外科学会癌症委员会对Medline文献进行协作综述,描述上尿路尿路上皮癌(UTUC)中微卫星不稳定/错配修复缺陷(MSI/dMMR)表型的遗传机制、检测方法、患病率及影响。该表型主要与Lynch综合征中MMR基因胚系突变相关,患病率1.7%–57%不等,患者可能预后更好、对化疗敏感性较低但对免疫治疗敏感性较高。
要点
- UTUC中MSI/dMMR主要机制为Lynch综合征MMR基因(MLH1、MSH2、MSH6、PMS2)胚系突变。
- 检测指征目前限于临床怀疑散发性UTUC者,仅胚系DNA测序阳性者转诊筛查该综合征。
- MSI/dMMR表型UTUC患病率1.7%–57%,取决于研究人群、检测方法和阳性判定标准。
核心结论
- 本协作综述总结了已发表研究中UTUC患者MSI/dMMR表型的现有数据,其中大多数研究证据水平较低。
研究设计与样本
- 法国泌尿外科学会癌症委员会对Medline可用文献进行协作综述,报告描述UTUC患者MSI/dMMR表型遗传机制、检测、患病率和影响的研究。
主要发现
- UTUC患者MSI/dMMR表型的主要遗传机制与Lynch综合征中MMR基因MLH1、MSH2、MSH6和PMS2一个等位基因的胚系突变相关。
- 尽管MSIsensor有价值,常规用于体细胞检测MSI和dMMR表型的技术分别仅为PCR和免疫组化。
- UTUC患者MSI/dMMR表型患病率范围为1.7%至57%,取决于研究人群、检测方法和阳性检测定义。
- 初诊时较年轻年龄和更平衡的男女比例是MSI/dMMR表型UTUC患者的主要特异性临床特征。
- 尽管文献结果存在冲突,这些患者可能预后更好,可能与更有利的病理特征相关;他们可能对化疗敏感性较低但对免疫治疗敏感性较高。
关键数值与推荐
- 检测指征目前限于临床怀疑散发性UTUC的患者,仅将胚系DNA测序阳性者转诊筛查Lynch综合征。
- 体细胞检测MSI常规使用PCR,检测dMMR表型常规使用免疫组化。
- UTUC患者MSI/dMMR表型患病率范围为1.7%至57%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 大多数研究证据水平较低。
- 文献中关于预后和化疗敏感性的结果存在冲突。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To perform a collaborative review of the literature exploring the microsatellite instability/deficient mismatch repair (MSI/dMMR) phenotype in patients with upper tract urothelial carcinoma (UTUC). METHOD: A collaborative review of the literature available on Medline was conducted by the Cancer Committee of the French Association of Urology to report studies describing the genetic mechanisms, investigation, prevalence and impact of the MSI/dMMR phenotype in UTUC patients. RESULTS: The predominant genetic mechanism leading to the MSI/dMMR phenotype in UTUC patients is related to the constitutional mutation of one allele of the MMR genes MLH1, MSH2, MSH6 and PMS2 within Lynch syndrome. Indications for its investigation currently remain limited to patients with a clinical suspicion for sporadic UTUC to refer only those with a positive testing for germline DNA sequencing to screen for this syndrome. With regard to technical aspects, despite the interest of MSIsensor, only PCR and immunohistochemistry are routinely used to somatically investigate the MSI and dMMR phenotypes, respectively. The prevalence of the MSI/dMMR phenotype in UTUC patients ranges from 1.7% to 57%, depending on the study population, investigation method and definition of a positive test. Younger age and a more balanced male to female ratio at initial diagnosis are the main specific clinical characteristics of UTUC patients with an MSI/dMMR phenotype. Despite the conflicting results available in the literature, these patients may have a better prognosis, potentially related to more favourable pathological features. Finally, they may also have lower sensitivity to chemotherapy but greater sensitivity to immunotherapy. CONCLUSION: Our collaborative review summarises the available data from published studies exploring the MSI/dMMR phenotype in UTUC patients, the majority of which are limited by a low level of evidence.
引用
- Gabriel PE, Cancel-Tassin G, Audenet F, et al. A collaborative review of the microsatellite instability/deficient mismatch repair phenotype in patients with upper tract urothelial carcinoma. BJU Int. 2024. PMID: 38813615. doi:10.1111/bju.16405
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。